Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. sti-001

STI-001 SIGNED

Turn Cancer Immunotherapy Effective in Most Patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 STI-001 project word cloud

Explore the words cloud of the STI-001 project. It provides you a very rough idea of what is the project "STI-001" about.

rates    answer    shown    unresponsive    vlps    2m    stimunity    interferon    stimulatory    letters    survival    regulatory    checkpoint    distant    edge    encapsulates    natural    vlp    cancer    validate    marketing    restores    named    drugs    immuno    biological    001    inhibitors    first    update    licensing    innate    raised    nevertheless    showed    kill    inducing    worldwide    disruptive    cancers    strategy    manufacturing    confirm    cells    pharmaceutical    intent    sting    leader    patients    weakened    ligand    50    unseen    beginning    weaker    sti    demonstrated    safe    fires    cutting    private    date    pipeline    companies    smei1    durable    immunotherapy    larger    metastatic    potent    activate    chemical    business    company    stimulator    public    tumour    competitors    develops    proprietary    tumor    physicians    plan    fto    restore    virus    million    anti    immune    particle    create    feasibility    therapeutic    ligands    genes    option    see    tumours   

Project "STI-001" data sheet

The following table provides information about the project.

Coordinator		 STIMUNITY SAS 

Organization address
address: RUE D'AMSTERDAM 57
city: PARIS
postcode: 75008
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STIMUNITY SAS FR (PARIS) coordinator 50˙000.00

Map

 Project objective

Stimunity is a company that develops disruptive immuno-stimulatory biological drugs to restore the immune system against tumor cells. Immune checkpoint inhibitors showed great potential in cancer immunotherapy after achieving 5-year survival rates for patients with advanced or metastatic cancers, unseen by physicians before. This is a promising beginning. Nevertheless, 5 million patients worldwide remain unresponsive to immunotherapy and do not have any other therapeutic option. On average it represents 50% of all cancers. A promising answer to this problem is the development of new drugs that activate the STING (STimulator of INterferon Genes) pathway, which fires up the innate immune system of these unresponsive patients, inducing a potent and durable anti-tumour immune response. It is expected to be effective on a much larger number of cancer patients. Stimunity’s first product, named STI-001, restores weakened immune systems to kill tumour cells. It is especially effective on distant tumours. Competitors using chemical STING ligands have shown a much weaker immune response than STI-001. STI-001 is based on a safe cutting-edge Virus-Like Particle (VLP) technology that encapsulates the best-known natural STING ligand and efficiently deliver it into immune cells. There is high interest in STI-001, as demonstrated by public and private funding (raised €2.2M to date) and advanced discussions with major pharmaceutical companies (see Letters of Intent). SMEi1 project will allow Stimunity to i) confirm the technical feasibility of manufacturing STI-001, (ii) update the FTO, (iii) assess regulatory issues, (iv) validate the marketing and business plan. Our long-term goal is to develop a pipeline of products based on proprietary VLPs in cancer immunotherapy and create a long term out-licensing strategy as a worldwide leader in VLP-based immunotherapy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STI-001" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STI-001" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

RoboSynFarm (2019)

Robotic Synthesis Farm

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More